In part 2 of this article, results from the testing of a next generation convecdiff membrane are discussed.
Chaz Goodwine
Advertisement
Chaz Goodwine is lead downstream scientist at AGC Biologics.
Articles by Chaz Goodwine
The testing of new convecdiff membranes shows this material to be well suited for lab- and commercial-scale bind-and-elute applications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
5